Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Innocan Pharma Announces 5,000 Units Sale and Expansion to Lithuania, Latvia & Estonia Markets - Happi
Company News, Marketing News

Innocan Pharma Announces 5,000 Units Sale and Expansion to Lithuania, Latvia & Estonia Markets

Per the multi-year agreement, UAB Medexy has an exclusive right to distribute both Innocan's SHIR and RELIEF&GO brands on an agreed purchase forecast.

Innocan Pharma Corporation has entered into of a wide-scope commercial distribution agreement with UAB Medexy.
 
Per the multi-year agreement, UAB Medexy has an exclusive right to distribute both Innocan's SHIR and RELIEF&GO brands in Lithuania, Latvia & Estonia, based on an agreed purchase forecast.
 
UAB Medexy's first order under the agreement is for over 5,000 units of SHIR and RELIEF&GO products.

A Key Eastern European Player in the Import and Distribution of Cosmetic Products 

UAB Medexy has a reputation as a key Eastern European player in the import and distribution of cosmetic products and medical devices. It has been highly active in the Lithuanian dermo-cosmetics market for the past 17 years, positioning it as one of the major players in its industry.
 
The CBD skin care market is estimated to reach $10.3 billion by 2028, according to the CBD skin care market Global Sales Analysis Report 2028 by Future Market Insights. Innocan Pharma and SHIR/ RELIEF&GO will now be stepping-up to become market leaders in many European countries. 
 
Said Iris Bincovich, CEO of InnoCan, “We are humbled to have a leading European market leader such as UAB Medexy as our market-partner in Lithuania, Latvia & Estonia. This new business will complement both Innocan's exponential growth strategy and UAB Medexy Health and Beauty market strategy.”
 

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters